Among 60 patients with T2DM and NAFLD, sitagliptin + metformin therapy led to significantly greater improvements in FBS, TC, TG, SGPT, vitD3, and TG-G index compared with the metformin monotherapy group. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.